Works matching IS 2160763X AND DT 2022 AND VI 11 AND IP 3

Results: 16

Bioequivalence and Safety of Levetiracetam Granules and Oral Solution: A Randomized, Single‐Dose, 2‐Period Crossover Study in Healthy Chinese Volunteers Under a Fasting Condition.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 3, p. 372, doi. 10.1002/cpdd.1063

By:

Liu, Yun;
Zou, Yang;
Wang, Yijun;
Jiang, Fan;
Xu, Wenjing;
Liu, Shuyun;
Jia, Jingying;
Yu, Chen;
Fang, Liming;
Hu, Liwei;
Zhang, Kanyin E.;
Long, Jingwen;
Pu, Huahua

Publication type:

Article

List of Reviewers 2021.

Published in:: Clinical Pharmacology in Drug Development, 2022, v. 11, n. 3, p. 413, doi. 10.1002/cpdd.1080
Publication type:: Article

Issue Information.

Published in:: Clinical Pharmacology in Drug Development, 2022, v. 11, n. 3, p. 291, doi. 10.1002/cpdd.825
Publication type:: Article

Pharmacokinetics, Safety, and Pharmacodynamics of Romiplostim in Chinese Subjects With Immune Thrombocytopenia: A Phase I/II Trial.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 3, p. 379, doi. 10.1002/cpdd.1059

By:

Qi, Junyuan;
Zheng, Li;
Hu, Bei;
Zhou, Hu;
He, Qing;
Liu, Hong;
Kawai, Hironori;
Yang, Renchi

Publication type:

Article

Phase I Study of the Pharmacodynamics and Safety of Sodium Zirconium Cyclosilicate in Healthy Chinese Adults.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 3, p. 348, doi. 10.1002/cpdd.1055

By:

Cheung, Tommy;
Sun, Fang;
Zhao, June;
Qin, Yulin;
Någård, Mats

Publication type:

Article

Assessment of Pharmacokinetic Interaction Between Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 3, p. 406, doi. 10.1002/cpdd.1047

By:

McCrea, Jacqueline B.;
Hussain, Azher;
Ma, Bennett;
Garrett, Graigory C.;
Evers, Raymond;
Laabs, John E.;
Stoch, S. Aubrey;
Iwamoto, Marian

Publication type:

Article

Phase 1 Maximal Use Pharmacokinetic Study of Tirbanibulin Ointment 1% in Subjects With Actinic Keratosis.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 3, p. 397, doi. 10.1002/cpdd.1041

By:

Yavel, Regina;
Overcash, J. Scott;
Cutler, David;
Fang, Jane;
Zhi, Jay

Publication type:

Article

Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson Disease.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 3, p. 324, doi. 10.1002/cpdd.1039

By:

Wilbraham, Darren;
Biglan, Kevin M.;
Svensson, Kjell A.;
Tsai, Max;
Pugh, Melissa;
Ardayfio, Paul;
Kielbasa, William

Publication type:

Article

Bioequivalence Assessment of an Oral Fixed‐Dose Formulation of Dutasteride‐Tamsulosin 0.5 mg/0.4 mg: A Randomized, Single‐Blind, Single‐Dose, 2‐Period Crossover Study in Mexican Population Under Fasted Conditions.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 3, p. 318, doi. 10.1002/cpdd.1011

By:

Piñeyro‐Garza, Everardo;
Gómez‐Silva, Magdalena;
Gamino, María E.;
Delgado‐Roche, Livan

Publication type:

Article

Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 3, p. 388, doi. 10.1002/cpdd.1028

By:

Trivedi, Ashit;
Sohn, Winnie;
Hsu, Cheng‐Pang;
Jafarinasabian, Pegah;
Zhang, Hanze;
Hutton, Shauna;
Flach, Stephen;
Abbasi, Siddique;
Dutta, Sandeep;
Lee, Edward

Publication type:

Article

Blood Pressure Recovery After Dobutamine Antagonism: Partial With Landiolol, None With Esmolol.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 3, p. 309, doi. 10.1002/cpdd.1025

By:

Krumpl, Günther;
Ulč, Ivan;
Trebs, Michaela;
Kadlecová, Pavla;
Hodisch, Juri;
Husch, Bernhard

Publication type:

Article

Pharmacokinetics, Safety, and Tolerability of the α<sub>2C</sub>‐Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 3, p. 296, doi. 10.1002/cpdd.1018

By:

Kapsa, Stefanie;
Thuss, Uwe;
Boxnick, Stefanie;
Schaumann, Frank;
Schultz, Armin;
Unger, Sigrun;
Otto, Christiane

Publication type:

Article

Pharmacokinetics of Flunarizine Hydrochloride After Single Oral Doses in Healthy Subjects: Bioequivalence Study and Food Effects.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 3, p. 341, doi. 10.1002/cpdd.1012

By:

Xu, Yan‐Ying;
Yi, Zhi‐Heng;
Li, Xiao‐Min;
Li, Dai;
Pan, Lin;
Dai, Yi‐Xin;
Zhong, Xue‐Feng;
Yan, Juan;
Xu, Ping‐Sheng;
Xu, Su‐Mei

Publication type:

Article

Bioequivalence and Food Effect Assessment of 2 Rivaroxaban Formulations in Healthy Chinese Volunteers: An Open, Randomized, Single‐Dose, and 4‐Period Crossover Study.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 3, p. 358, doi. 10.1002/cpdd.1031

By:

Tao, Ye;
Jiang, Xin;
Shi, Ping;
Liu, Yanping;
Lin, Pingping;
Liu, Shuqin;
Li, Ting;
Ma, Yaping;
Gao, Xiaomeng;
Cao, Yu

Publication type:

Article

Pharmacokinetics of Sugammadex: An Open‐Label, 3‐Period, Fixed‐Sequence, 3‐Single‐Doses Study in Healthy Chinese Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 3, p. 333, doi. 10.1002/cpdd.1006

By:

Yuan, Fei;
Yang, Mengjie;
Chen, Weili;
Chen, Hanjing;
Xu, Hongrong;
Li, Hui;
Sheng, Lei;
Li, Xuening;
Ellen Wrishko, Rebecca;
Joel Woolf, Eric

Publication type:

Article

A Dose‐Confirmation Phase 1 Study to Evaluate the Safety and Pharmacology of Glucarpidase in Healthy Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 3, p. 364, doi. 10.1002/cpdd.1010

By:

Fukaya, Yutaka;
Kimura, Toshimi;
Yoshimura, Kenichi;
Umemura, Kazuo;
Kawamoto, Hiroshi

Publication type:

Article